Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Oct
01
Today In Oncology
Depression Increases Cancer-Specific Mortality Risks in Common Cancers
Real-World Data Indicate Lower Adherence Rates for Breast Cancer Endocrine Therapy When Radiation Therapy Is Omitted
SYMPRO-Lung: Could Weekly PRO Symptom Monitoring Improve Survival Outcomes in Any-Stage Lung Cancer?
Mindfulness and Tai Chi May Improve Symptoms After Cancer Treatment
Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo